Trastuzumab deruxtecan (T-DXd, DS-8201) in HER2-positive metastatic breast cancer previously treated with T-DM1: DESTINY-Breast01 study Meeting Abstract
| Authors: | Krop, I.; Manich, C. S.; Yamashita, T.; Park, Y. H.; Kim, S. B. K.; Tamura, K.; Andre, F.; Iwata, H.; Ito, Y.; Tsurutani, J.; Sohn, J.; Denduluri, N.; Perrin, C.; Aogi, K.; Tokunaga, E.; Im, S. A.; Lee, K. S.; Hurvitz, S.; Cortes, J.; Lee, C.; Chen, S.; Zhang, L.; Shahidi, J.; Yver, A.; Modi, S. |
| Abstract Title: | Trastuzumab deruxtecan (T-DXd, DS-8201) in HER2-positive metastatic breast cancer previously treated with T-DM1: DESTINY-Breast01 study |
| Meeting Title: | 2020 Swiss Oncology and Hematology Congress (SOHC) |
| Journal Title: | Swiss Medical Weekly |
| Volume: | 150 |
| Issue: | Suppl. 247 |
| Meeting Dates: | 2020 Nov 18-21 |
| Meeting Location: | Virtual |
| ISSN: | 1424-7860 |
| Publisher: | E M H Swiss Medical Publishers Ltd |
| Date Published: | 2020-11-17 |
| Start Page: | 25 S |
| Language: | English |
| ACCESSION: | WOS:000592781900060 |
| PROVIDER: | wos |
| PUBMED: | 33200807 |
| DOI: | 10.4414/smw.2020.20411 |
| Notes: | Meeting Abstract: P40 -- Source: Wos |
